Constipation, a common symptom in clinical practice, affects up to 20% of the world's population. It has a significant impact on patient's quality of life and healthcare resources. With advancements in medical knowledge and technology, there is a need to revisit our approach to constipation.
Traditionally, constipation is diagnosed based on clinical symptoms and Rome IV criteria. However, this approach often overlooks underlying pathophysiology. Modern techniques such as high-resolution anorectal manometry and transluminal impedance measurement can provide detailed information about the functional status of the colon and rectum, aiding in accurate diagnosis.
Treatment should be tailored to the individual patient's needs. Lifestyle modifications and over-the-counter laxatives are the first-line treatments. However, for patients with refractory symptoms, newer pharmacological agents like linaclotide and plecanatide, which increase intestinal fluid secretion and transit, can be beneficial.
Biofeedback therapy, which uses sensors to make patients aware of physiological functions, has proven effective in treating pelvic floor dyssynergia, a common cause of constipation. This non-invasive therapy can be a game-changer for patients who do not respond to traditional treatments.
For patients with severe, refractory constipation, surgical interventions such as sacral nerve stimulation and subtotal colectomy are being increasingly considered. These procedures, although invasive, can significantly improve symptoms and quality of life in select patients.
In conclusion, the approach to constipation has evolved significantly over the years. Modern diagnostic tools allow for a more precise understanding of the pathophysiology, leading to personalized treatment plans. Innovative therapies and surgical approaches hold promise for patients with refractory symptoms. As healthcare professionals, we must stay abreast of these advancements to provide optimal patient care.
1.
Stem Cell Selection Unneeded for SSc Transplant Therapy?
2.
Radiation from CT scans could account for 5% of all cancer cases a year, study suggests
3.
Do I have prostate cancer? Why a simple PSA blood test alone won't give you the answer
4.
In Hemophilia A and B, a Novel Monoclonal Antibody Reduces Bleeding.
5.
Tumor infiltration of major blood vessels, not metastasis, may be primary cause of cancer death
1.
Revolutionizing Oncology Trials: Optimization, Matching, Diversity, and Decentralization
2.
Emerging Dysregulated Signaling Pathways in Early-Onset Colorectal Cancer
3.
Exploring the Use of Bevacizumab in Treating Different Types of Cancers
4.
A Closer Look at Poorly Differentiated Carcinoma: Uncovering its Complexities
5.
Unlocking the Secrets of Squamous Cell Carcinoma: New Hope for Patients
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
2.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
3.
A New Era in Managing Cancer-Associated Thrombosis
4.
Navigating the Complexities of Ph Negative ALL - Part IX
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation